Skip to main content
OpenTrials
Completed

NCT Number: NCT02760771

Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)

Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is often performed under rapid right ventricular pacing (burst >180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation aims at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects.

There is limited experience for the balloon expandable Edwards THV on the need for predilation (BAV). Experience so far has only been documented from smaller, uncontrolled case series.

The investigators aim to document the incidence of several kinds of complications in a large, multicenter registry / prospective controlled cohort study to identify associations between patient related variables and outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medizinische Klinik IV, Städtisches Klinikum Karlsruhe

Karlsruhe, Baden-Wurttemberg, 76133, Germany

About this study

Aortic valve predilation aims at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as:

  • Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia.
  • In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality.
  • BAV has been identified as a major source of thrombotic and valvular material, thus increasing the risk for coronary obstruction with subsequent myocardial infarction and/or stroke.
  • The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture.

The investigators aim to document the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a large, multicenter registry / prospective controlled cohort study to identify associations between patient related variables and outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Males or females
  • At least 18 years of age

Exclusion criteria

  • Logistic EuroSCORE I >40%
  • Mitral or tricuspid valvular insufficiency (> grade II)
  • Previous aortic valve replacement
  • Uncontrolled atrial fibrillation
  • Left ventricular or atrial thrombus by echocardiography
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
  • Patients with mobile structures on the leaflets
  • Need for a cerebral protection device

Treatment and study plan

with BAV

Other

balloon dilation of the aortic valve prior to implantation of the THV

without BAV

Other

no balloon dilation of the aortic valve prior to implantation of the THV

Primary outcomes

  1. Combination of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantation

    Time frame: within 30 days after TAVI

Secondary outcomes

  1. All-cause mortality

    Time frame: within 30 days after TAVI

  2. Stroke

    Time frame: within 30 days after TAVI

  3. Non-fatal myocardial infarction

    Time frame: within 30 days after TAVI

  4. pacemaker implantation

    Time frame: within 30 days after TAVI

  5. acute kidney injury

    Time frame: within 30 days after TAVI

Sponsors and collaborators

Lead sponsor

Institut für Pharmakologie und Präventive Medizin

Network

Registry information

Acronym: EASE-IT-TF

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 4, 2016
Registry last updated
Feb 28, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.